コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 lzheimer's disease (AD), since it drives the cognitive decline.
2 episodes, and obsessive behavior, as well as cognitive decline.
3 terventions for alleviating hearing loss and cognitive decline.
4 atrophy is an early sign of potential future cognitive decline.
5 gether determining an individual's course of cognitive decline.
6 (AD), often arising years before symptoms of cognitive decline.
7 aracterized by accelerated tau pathology and cognitive decline.
8 tive function at baseline and lower rates of cognitive decline.
9 eing is an integral component of age-related cognitive decline.
10 "mostly" drinking trajectories with 15-year cognitive decline.
11 gross infarcts) were associated with global cognitive decline.
12 likely do not greatly influence preclinical cognitive decline.
13 dative stress and inflammation, 2 drivers of cognitive decline.
14 composite of sex-differentiated tau ROIs and cognitive decline.
15 stable, heavy drinking with greater 15-year cognitive decline.
16 y be a novel therapeutic approach to prevent cognitive decline.
17 in midlife may be associated with less 20-y cognitive decline.
18 Abeta and tau pathology, and predicts future cognitive decline.
19 changes such as anxiety and depression, and cognitive decline.
20 may alter circuit function and contribute to cognitive decline.
21 tly been implicated in neurodegeneration and cognitive decline.
22 r signaling in the hippocampus, resulting in cognitive decline.
23 a visually impaired population to slow this cognitive decline.
24 human structural connectome in aging-related cognitive decline.
25 aggregates are implicated in neuron loss and cognitive decline.
26 Exercise is known to prevent cognitive decline.
27 vel of cognitive functioning but not rate of cognitive decline.
28 Hcy to methionine and reduces age-dependent cognitive decline.
29 velop treatments to help reduce, age-related cognitive decline.
30 he white matter and eventually contribute to cognitive decline.
31 ression of Nr4a2 contributing to age-related cognitive decline.
32 ease biomarkers and their relationships with cognitive decline.
33 aptive immune pathways, which correlate with cognitive decline.
34 o medications prevent or reverse age-related cognitive decline.
35 cal setting as part of a strategy to prevent cognitive decline.
36 at contribute to accelerated memory loss and cognitive decline.
37 linked to tau aggregation and could promote cognitive decline.
38 tau-related neuropathology, and the rate of cognitive decline.
39 dedifferentiation contributes to age-related cognitive decline.
40 or more than 3.5 hours per day is related to cognitive decline.
41 tical thinning and subsequently longitudinal cognitive decline.
42 ta aggregation is associated with subsequent cognitive decline.
43 Over time, these changes are associated with cognitive decline.
44 yses, and 861 individuals in the analyses of cognitive decline.
45 onse, ultimately leads to neuronal death and cognitive decline.
46 uggested to have a role in the prevention of cognitive decline.
47 neurodegenerative disease, concomitant with cognitive decline.
48 ission to an ICU may subsequently experience cognitive decline.
49 oinflammation and alleviate aging-associated cognitive decline.
50 ts the major pathophysiological correlate of cognitive decline.
51 uent neocortical change that correlated with cognitive decline.
52 myloid plaques, neurofibrillary tangles, and cognitive decline.
53 to identify individuals at greatest risk for cognitive decline.
54 y prevention for many of the risk factors of cognitive decline.
55 o communication difficulties, isolation, and cognitive decline.
56 logic findings, and some are associated with cognitive decline.
57 xcluded from the optimal predictive model of cognitive decline.
58 ospinal fluid and positively correlates with cognitive decline.
59 's disease (AD), contributing to progressive cognitive decline.
60 No approved treatments exist for age-related cognitive decline.
61 e of alpha7beta2-nAChR in oAbeta(42)-induced cognitive decline.
62 ions for blood-brain barrier dysfunction and cognitive decline.
63 dividuals with SCD will not show progressive cognitive decline.
64 for adults age 65 or older with age-related cognitive decline.
65 dual contributions of amyloid and tau affect cognitive decline.
66 s, low baseline intellectual functioning and cognitive decline.
67 cantly contributed to greater risk of faster cognitive decline.
68 olecular processes that eventually result in cognitive decline.
69 lted in synaptic phagocytosis and subsequent cognitive decline.
70 wider application to this and other forms of cognitive decline.
71 of synaptic density that was associated with cognitive decline.
72 1MO was associated with delirium and greater cognitive decline.
73 ous factors contributed to MCI and predicted cognitive declined.
74 ed risk of developing lasting functional and cognitive declines.
77 nic population (total n = 111, 60 subjective cognitive decline, 36 mild cognitively impaired, and 19
78 0.39% [95% CI, 0.09%-0.68%]; I2 = 0.0%) and cognitive decline (8 trials) (20.2% vs 21.1% of particip
80 m was to investigate the pattern and rate of cognitive decline across distinctive trajectories of dep
81 urgery were at higher risk of functional and cognitive declines [adjusted odds ratio (aOR) 1.52, 95%
83 are at higher risk of lasting functional and cognitive decline after surgery, and the impact of decli
84 Understanding whether these features predict cognitive decline, alone or in combination, is crucial t
85 The relationship between ethanol intake and cognitive decline, although studied extensively, remains
90 ber of individuals affected with age-related cognitive decline and Alzheimer's disease (AD) has incre
94 As our brains age, we tend to experience cognitive decline and are at greater risk of neurodegene
96 that nec-1 and metformin equally attenuated cognitive decline and brain pathologies in prediabetic r
99 496) were women with the 10% worst slopes of cognitive decline and controls (n=7,478) those with slop
100 ons (including multimorbidity, polypharmacy, cognitive decline and delirium, and frailty) may be inad
101 isk for myriad health consequences including cognitive decline and dementia, but research on the link
106 ssociate inflammation from neuronal loss and cognitive decline and demonstrate that neuronal PTP1B ha
108 hen excessive is associated with accelerated cognitive decline and depression, helping identify those
109 myloid-beta was associated with a more rapid cognitive decline and earlier mortality, and in the stri
112 developed to counteract irradiation-induced cognitive decline and improve patient quality of life.
114 absence of dementia, also results in gradual cognitive decline and is thought to arise, in part, beca
115 ascular morbidity and mortality but also for cognitive decline and loss of autonomy later in life.
116 ow social isolation and loneliness relate to cognitive decline and may contribute to new directions f
117 shows that sleep disturbance contributes to cognitive decline and might also increase the risk of Al
118 on-targeted ablation of PTP1B also prevented cognitive decline and neuron loss but did not reduce inf
123 significant correlations between the rate of cognitive decline and the first component of each imagin
125 brain injuries (TBI) and is characterized by cognitive decline and the presence of neurofibrillary ta
127 ies are needed to understand mechanism(s) of cognitive decline and to enable better treatment algorit
130 ded in the primary meta-analysis, 8 reported cognitive decline, and 8 reported changes in cognitive t
133 P predict the development of sporadic AD and cognitive decline, and changes in structural brain chara
134 rs and memantine slightly reduced short-term cognitive decline, and cholinesterase inhibitors slightl
135 496) were women with the 10% worst slopes of cognitive decline, and controls (n = 7,478) were those w
137 n was associated with cognitive performance, cognitive decline, and dementia/ cognitive impairment wi
138 a novel method to estimate hours of greatest cognitive decline, and have implications for policy arou
139 ve biomarker for delirium risk and long-term cognitive decline, and once confirmed would provide path
140 king would be associated with lesser 15-year cognitive decline, and stable, heavy drinking with great
141 hospitalizations experienced faster rates of cognitive decline, and this association was more pronoun
142 r surgery was associated with functional and cognitive decline, and whether declines were associated
143 olism, inflammatory cytokine production, and cognitive decline; and they provide a potential mechanis
144 kers in those at risk for AD and age-related cognitive decline (ARCD) in order to develop preventativ
145 evention trials of measures to halt or delay cognitive decline are increasingly recruiting older indi
148 timate the effects of each neuropathology on cognitive decline as assessed by the mini-mental state e
149 with renal dysfunction have been linked with cognitive decline as the kidneys and brain share compara
150 ements or whether they experience subsequent cognitive decline as they age with a functioning graft.
151 the latest findings in approaches to prevent cognitive decline as well as dementia screening, diagnos
152 peutic strategy in preventing progression of cognitive decline associated with AD and related dementi
153 ombination of neurological, psychiatric, and cognitive decline associated with calcium deposition on
155 s are the average difference in standardized cognitive decline associated with infarctions versus no
158 were significantly associated with long-term cognitive decline at 3 months, but none of the PC constr
160 s at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49,
161 -0.24, SE = 0.12), and between diabetes and cognitive decline (B = -0.66, SE = 0.27; p < 0.05 for bo
162 th increased life expectancy, age-associated cognitive decline becomes a growing concern, even in the
163 hort exhibited significantly slower rates of cognitive decline (beta^ = 0.50, 95% CI: 0.39, 0.62) and
164 condary outcomes included delirium duration, cognitive decline, breakthrough analgesia within the fir
165 e-related eye disease may be associated with cognitive decline, but the scientific literature has not
166 merous ageing-associated diseases, including cognitive decline, cancer, metabolic disease, sarcopenia
167 ests that the pattern as well as the rate of cognitive decline co-occurs with specific patterns of ch
169 ission was associated with greater long-term cognitive decline compared with patients without ICU adm
170 talized for critical illness develop greater cognitive decline compared with those who do not require
171 ry would differ in patients having long-term cognitive decline defined as a composite cognitive z sco
174 and thus, our objective was to determine how cognitive decline differs longitudinally between these t
175 ct of immune homeostasis on neurogenesis and cognitive decline during brain aging have not been previ
176 amma mediating microglia activation triggers cognitive decline during recovery from Zika virus (ZIKV)
177 eatures included progressive ataxia, tremor, cognitive decline, dysphagia, optic atrophy, dysarthria,
178 it was strongly associated with the rate of cognitive decline (e.g., global cognition: beta [SE] = -
180 spitalization was associated with more rapid cognitive decline (estimate = -0.042, standard error [SE
182 made a significant prediction of the rate of cognitive decline from age 70 to 79 (standardized beta =
185 n between family member migration status and cognitive decline; future work should be extended to oth
187 link between genomic retroviral elements and cognitive decline; however, in mammals, the role of ERVs
192 entification of the neurobiological bases of cognitive decline in aging populations may provide criti
194 rrelation between volumetric MRI changes and cognitive decline in all groups including placebo at Wee
195 mpairment both contribute importantly to the cognitive decline in Alzheimer's disease (AD), but wheth
197 added value of PET biomarkers in predicting cognitive decline in Alzheimer's disease, over and above
201 in the cerebrospinal fluid predicted future cognitive decline in APOE4 carriers but not in non-carri
202 the development of the AD-like pathology and cognitive decline in DS, and for this reason the system
203 in hypertension, type 2 diabetes (T2D), and cognitive decline in experimental models of IH patterned
206 ime in the temporal lobe was associated with cognitive decline in individuals with Alzheimer disease.
207 as well as the pace of biological aging and cognitive decline in longitudinal data from childhood to
208 Synapse loss is associated with motor and cognitive decline in multiple neurodegenerative disorder
209 ynaptodendritic pruning is a common cause of cognitive decline in neurological disorders, including H
210 sk, aiming to reduce the risk of age-related cognitive decline in non-Mediterranean populations.
211 matter tracts are associated with memory and cognitive decline in normal aging and mild cognitive imp
213 ervention strategy for combating age-related cognitive decline in otherwise healthy individuals.
214 s; this co-occurrence suggests that onset of cognitive decline in Parkinson's disease may be associat
215 , and in the prevention of vascular-mediated cognitive decline in patients with atrial fibrillation.
216 a may contribute to behavioral phenotype and cognitive decline in patients with sleep-disordered brea
217 anterior temporal neuroinflammation predict cognitive decline in patients with symptomatic Alzheimer
218 , a validated clinical algorithm for risk of cognitive decline in PD, measures of visuoperceptual fun
220 thological amyloid and tau is detrimental to cognitive decline in preclinical Alzheimer's disease dur
222 illary tangles is believed to correlate with cognitive decline in several neurodegenerative disorders
224 nsfer, plays an important role in explaining cognitive decline in SVD, which was however not independ
225 possibly clear tau tangles and modestly slow cognitive decline in symptomatic Alzheimer's disease (AD
226 agnosis of AD, its severity, and the rate of cognitive decline in the 12 years prior to death in subj
228 23:0), and lignoceric acid (24:0)] with 20-y cognitive decline in the Atherosclerosis Risk in Communi
229 ulation were associated with faster rates of cognitive decline in the cognitively unimpaired subgroup
230 to maintaining cognitive function and delay cognitive decline in the elderly, but physical fitness (
231 l group, we identified those who experienced cognitive decline in the later years (AUC = 0.804, sensi
235 n of the BBB contributes to APOE4-associated cognitive decline independently of Alzheimer's disease p
237 ance deficits are the core symptoms of SCA1, cognitive decline is also commonly observed in patients.
239 tween Alzheimer's disease (AD) pathology and cognitive decline is an important topic in the aging res
245 and larger infarctions may escalate risk for cognitive decline later in life in stroke-free persons.
246 rotein track well with neurodegeneration and cognitive decline, making the imaging of aggregated tau
248 le of CRP in cognitive decline using a proxy cognitive decline metric, defined as the difference betw
250 ing Abeta, including a group with subjective cognitive decline (N = 149, FACEHBI study) and a group r
251 hatase using a selective inhibitor prevented cognitive decline, neuron loss in the hippocampus, and a
254 gically measure sleep patterns and predicted cognitive decline of nurses working both 12hr day and ni
255 rylated tau in the brain correlates with the cognitive decline of patients of AD and other neurodegen
256 ociations between risk factors and late-life cognitive decline on a global scale, including compariso
257 regressed the individuals' estimated rate of cognitive decline on the neuroimaging components and exa
259 ciation with cognitive function at baseline, cognitive decline or with conversion rates to dementia b
260 Serum biomarkers were associated with faster cognitive decline over 16 years; baseline t-tau > 0.40pg
261 57 SD (95% CI: 0.018, 0.096, P = 0.004) less cognitive decline over 20 y as measured by WFT score.
262 rtisol) and their relationship with rates of cognitive decline over an 18 month follow up period and
264 .09% across cohorts) pathologies, and 1-year cognitive decline (p=0.0015) and hippocampal atrophy (p=
265 unimpaired) were highly predictive of future cognitive decline, pathological tau accumulation, neurod
266 Clarification of how delirium may cause cognitive decline, perhaps through evidence of contempor
270 fibrillation (AF) have an increased risk of cognitive decline, potentially resulting from clinically
271 of Alzheimer's disease that can precede the cognitive decline, raising the possibility that amyloid-
274 suggest that memory deficits and accelerated cognitive decline reported in previous studies of LLD ar
275 e are not associated with lesser and greater cognitive decline, respectively, from mid- to late life
276 and when applied to patients with subjective cognitive decline (SCD) or mild cognitive impairment (MC
277 D mortality rates, AD prevalence, subjective cognitive decline (SCD) prevalence, and oral health data
280 nts both with and patients without long-term cognitive decline showed early transient increases of th
281 dependently and they independently predicted cognitive decline.SIGNIFICANCE STATEMENT This study offe
282 mutation also protects from aging-dependent cognitive decline, suggesting that similar mechanisms un
283 patients will experience an even more rapid cognitive decline than AD patients without psychosis (AD
284 hat primary age-related tauopathy has slower cognitive decline than Alzheimer's disease across multip
286 s contributed to a significant proportion of cognitive decline that accelerated with longer follow-up
288 t the association between high-fat diets and cognitive decline, this study aimed to determine the eff
292 ained using latent growth mixture modelling, cognitive decline was assessed using smoothing splines a
295 rtioxetine may be beneficial for age-related cognitive decline when combined with cognitive training.
296 emotor signs, such as sleep disturbances and cognitive decline, which are key non-motor features of t
297 el, and sleep time play an important role in cognitive decline, which is consistent with the previous
298 antly high depressive symptoms showed linear cognitive decline, while those with constantly low and d
299 signaling is perhaps associated with normal cognitive decline with age as well as with Alzheimer's d